Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Premarin (Conjugated Estrogens,USP) for Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2012

Summary View

 

CONTRAINDICATIONS

  • Known anaphylactic reaction or angioedema to Premarin Intravenous Therapy
  • Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
 

WARNINGS

  • Anaphylactic reaction and angioedema
  • Hereditary angioedema
 

PATIENT INFORMATION

Who Should not use Premarin Intravenous?
  • Have been diagnosed with a bleeding disorder
 

 

-
-